ADCT 502 - ADC Therapeutics

Drug Profile

ADCT 502 - ADC Therapeutics

Alternative Names: ADCT 502 ADC Therapeutics

Latest Information Update: 03 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Developer ADC Therapeutics
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Apr 2017 Phase-I clinical trials in Solid tumours in USA (IV) (NCT03125200)
  • 05 Jan 2017 Preclinical trials in Solid tumours in United Kingdom (IV) (ADC Therapeutics pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top